MedTrace Logo

Aspirin in Young Psychotic Patients

NCT02685748 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-09-23

Study results available
· View outcomes & findings →

Summary

In this double blind randomized clinical trial the investigators are going to exam influence of adjuvant Aspirin therapy on soft neurological signs (Heidelberg scale), positive and negative symptoms (PANSS), cytokine profile and inflammatory factors, as well as on cognition (MoCA) in young psychotic patients.

Conditions

Interventions

DRUG

Aspirin

1000 mg pd in two doses

DRUG

Placebo

two pills twice a day (instead of aspirin and pantoprazole)

DRUG

Pantoprazole

Pantoprazole 40 mg/pd in two doses, for gastric protection

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • Clinic for Psychiatric Disorders, Dr Laza Lazarevic

    lead OTHER

Principal Investigators

  • Dragana Pavićević, psychiatrist · Clinic for psychiatric disorder Dr Laza Lazarević

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
28 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-20
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Serbia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02685748 on ClinicalTrials.gov